Bevacizumab plus Fotemustine as First-line Treatment in Metastatic Melanoma Patients: Clinical Activity and Modulation of Angiogenesis and Lymphangiogenesis Factors - Concepedia

Concepedia

Publication | Closed Access

Bevacizumab plus Fotemustine as First-line Treatment in Metastatic Melanoma Patients: Clinical Activity and Modulation of Angiogenesis and Lymphangiogenesis Factors

58

Citations

28

References

2010

Year

Michele Del Vecchio, Roberta Mortarini, Stefania Canova, Lorenza Di Guardo, Nicola Pimpinelli, M. R. Sertoli, Davide Bedognetti, Paola Queirolo, Paola Morosini, Tania Perrone,

Clinical Cancer Research

Abstract

The combination of bevacizumab plus fotemustine has clinical activity in advanced melanoma and promotes systemic modulation of angiogenesis and lymphangiogenesis factors.

References

	Year	Citations

Page 1